TrialClinical cancer research : an official journal of the American Association for Cancer Research2014

Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.

Nitin Jain et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.